{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:12:04Z","timestamp":1788455524270,"version":"build-2803163510"},"reference-count":276,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Viral hemorrhagic fevers (VHFs) comprise a heterogeneous group of severe infectious diseases that continue to represent a major global health concern. Although many VHFs remain endemic to regions of Africa, Asia, and the Americas, their wide geographic distribution, together with increasing international travel and global trade, facilitates the importation of cases into non-endemic areas and raises the risk of secondary transmission under favorable ecological and epidemiological conditions. These infections are frequently associated with high case-fatality rates and impose a substantial social and economic burden, including pressure on healthcare systems, disruption of essential services, and long-term physical and psychological sequelae among survivors. Despite notable advances in recent years, therapeutic options for VHFs remain limited. Supportive care continues to represent the cornerstone of clinical management for most infections, while pathogen-targeted therapies are available only for a restricted number of diseases. Monoclonal antibody-based therapies have achieved the most significant regulatory success to date, particularly for Ebola virus disease. In parallel, several small-molecule antivirals have been investigated in preclinical and clinical settings, including during outbreak responses, although inconsistent efficacy and safety concerns have limited widespread approval. Vaccine development has progressed further, with licensed vaccines available for selected VHFs, including Ebola, yellow fever, and dengue, and multiple candidates based on diverse technological platforms advancing through clinical evaluation. In addition to summarizing current therapeutic and vaccine strategies, this review highlights pharmaceutical development considerations relevant to biologic therapeutics and selected vaccine platforms, including formulation stability, pharmacokinetic behavior, delivery routes, storage requirements, and logistical constraints affecting deployment during outbreak responses. Using a comparative cross-pathogen framework, the review synthesizes recent literature to identify translational gaps, regulatory challenges, and future priorities for the development of safer and more effective medical countermeasures against VHFs.<\/jats:p>","DOI":"10.3390\/pharmaceutics18040426","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:20:47Z","timestamp":1774884047000},"page":"426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-7311","authenticated-orcid":false,"given":"Dan","family":"Lupascu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2530-3801","authenticated-orcid":false,"given":"Andreea-Teodora","family":"Iacob","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Apotrosoaei","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-2789","authenticated-orcid":false,"given":"Ioana-Mirela","family":"Vasincu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-1863","authenticated-orcid":false,"given":"Florentina-Geanina","family":"Lupascu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-1484","authenticated-orcid":false,"given":"Oana-Maria","family":"Chirliu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1792-7139","authenticated-orcid":false,"given":"Bianca-Stefania","family":"Profire","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-4208","authenticated-orcid":false,"given":"Roxana-Georgiana","family":"Tauser","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-3023","authenticated-orcid":false,"given":"Lenuta","family":"Profire","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.crviro.2021.100009","article-title":"Viral Hemorrhagic Fever: Molecular Pathogenesis and Current Trends of Disease Management-an Update","volume":"2","author":"Mariappan","year":"2021","journal-title":"Curr. Res. Virol. Sci."},{"key":"ref_2","unstructured":"(2025, October 06). CDC About Viral Hemorrhagic Fevers, Available online: https:\/\/www.cdc.gov\/viral-hemorrhagic-fevers\/about\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Belhadi, D., El Baied, M., Mulier, G., Malvy, D., Mentr\u00e9, F., and Laou\u00e9nan, C. (2022). The Number of Cases, Mortality and Treatments of Viral Hemorrhagic Fevers: A Systematic Review. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010889"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hewson, R. (2024). Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies. Pathogens, 13.","DOI":"10.3390\/pathogens13100909"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.26719\/emhj.18.002","article-title":"Identifying Hotspots of Viral Haemorrhagic Fevers in the Eastern Mediterranean Region: Perspectives for the Emerging and Dangerous Pathogens Laboratory Network","volume":"24","author":"Altmann","year":"2018","journal-title":"East. Mediterr. Health J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-6981-4_1","article-title":"Global Spread of Hemorrhagic Fever Viruses: Predicting Pandemics","volume":"Volume 1604","author":"Salvato","year":"2018","journal-title":"Hemorrhagic Fever Viruses"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40409-018-0162-y","article-title":"Yellow Fever in Africa and the Americas: A Historical and Epidemiological Perspective","volume":"24","author":"Chippaux","year":"2018","journal-title":"J. Venom. Anim. Toxins Trop. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Liu, C.-H., Hu, Y.-T., Wong, S.H., and Lin, L.-T. (2022). Therapeutic Strategies against Ebola Virus Infection. Viruses, 14.","DOI":"10.3390\/v14030579"},{"key":"ref_9","unstructured":"(2025, October 13). Ebola Virus Disease. Available online: https:\/\/www.who.int\/health-topics\/ebola."},{"key":"ref_10","unstructured":"(2025, October 13). CDC Outbreak History, Available online: https:\/\/www.cdc.gov\/ebola\/outbreaks\/index.html."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104213","DOI":"10.1016\/j.amsu.2022.104213","article-title":"Ebola Virus Disease Outbreak in the Democratic Republic of the Congo: A Mini-Review","volume":"80","author":"Bisimwa","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1097\/MS9.0000000000002213","article-title":"National Burden of Ebola Virus Disease in Democratic Republic of the Congo: The Urgency to Act","volume":"86","author":"Ahmad","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e28986","DOI":"10.1002\/jmv.28986","article-title":"Inequitable Access to Ebola Vaccines and the Resurgence of Ebola in Africa: A State of Arts Review","volume":"95","author":"Lawal","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_14","unstructured":"(2025, October 17). CDC Ebola Outbreak in the DRC: Current Situation, Available online: https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/ebola\/situation-summary\/index.html."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Malik, S., Kishore, S., Nag, S., Dhasmana, A., Preetam, S., Mitra, O., Le\u00f3n-Figueroa, D.A., Mohanty, A., Chattu, V.K., and Assefi, M. (2023). Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges. Vaccines, 11.","DOI":"10.3390\/vaccines11020268"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106213","DOI":"10.1016\/j.micpath.2023.106213","article-title":"Ebola Virus Disease: A Narrative Review","volume":"181","author":"Letafati","year":"2023","journal-title":"Microb. Pathog."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola Virus Relapse Causing Meningoencephalitis: A Case Report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1500306","article-title":"Persistence of Ebola Virus in Ocular Fluid during Convalescence","volume":"372","author":"Varkey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1056\/NEJMoa1511410","article-title":"Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors\u2014Final Report","volume":"377","author":"Deen","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4149\/av_2021_409","article-title":"Ebola Virus Disease: Current Perception of Clinical Features, Diagnosis, Pathogenesis, and Therapeutics","volume":"65","author":"Siddiqui","year":"2022","journal-title":"Acta Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1473-3099(24)00673-X","article-title":"Ebola Disease: Bridging Scientific Discoveries and Clinical Application","volume":"25","author":"Rojek","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102685","DOI":"10.1016\/j.tmaid.2023.102685","article-title":"The Basic Reproduction Number (R0) of Ebola Virus Disease: A Systematic Review and Meta-Analysis","volume":"57","author":"Muzembo","year":"2024","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_23","first-page":"e74078","article-title":"The Development of Ebola Virus Outbreaks: A Review of Epidemiological Trends, Clinical Features, and Treatment Advances","volume":"16","author":"Mohd","year":"2024","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Salata, C., Calistri, A., Alvisi, G., Celestino, M., Parolin, C., and Pal\u00f9, G. (2019). Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses, 11.","DOI":"10.20944\/preprints201902.0209.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S1473-3099(22)00810-6","article-title":"Breakthrough Treatments for Ebola Virus Disease, but No Access\u2014What Went Wrong, and How Can We Do Better?","volume":"23","author":"Torreele","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","unstructured":"(2025, October 25). Treatment (Ebola Disease), WHO, Regional Office for Africa. Available online: https:\/\/www.afro.who.int\/node\/16969."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective Monotherapy against Lethal Ebola Virus Infection by a Potently Neutralizing Antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Taki, E., Ghanavati, R., Navidifar, T., Dashtbin, S., Heidary, M., and Moghadamnia, M. (2023). EbangaTM: The Most Recent FDA-Approved Drug for Treating Ebola. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1083429"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tshiani Mbaya, O., Mukumbayi, P., and Mulangu, S. (2021). Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.721328"},{"key":"ref_30","unstructured":"(2025, October 27). EbangaTM. Available online: https:\/\/www.ebanga.com\/."},{"key":"ref_31","unstructured":"(2026, March 10). EBANGA (Ansuvimab-Zykl) for Injection, for Intravenous Use. FDA Reference ID: 5502671, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761172s008lbl.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","article-title":"Structure of the Inmazeb Cocktail and Resistance to Ebola Virus Escape","volume":"31","author":"Rayaprolu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.coviro.2023.101339","article-title":"A Review of Broadly Protective Monoclonal Antibodies to Treat Ebola Virus Disease","volume":"61","author":"Rijal","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.coph.2021.07.020","article-title":"Therapeutics Development for Ebola Virus Disease: A Recent Scenario","volume":"60","author":"Chakraborty","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jiph.2022.01.005","article-title":"A Systematic Review of Ebola Virus Disease Outbreaks and an Analysis of the Efficacy and Safety of Newer Drugs Approved for the Treatment of Ebola Virus Disease by the US Food and Drug Administration from 2016 to 2020","volume":"15","author":"Sivanandy","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_37","unstructured":"(2025, October 27). Inmazeb\u00ae (Atoltivimab, Maftivimab and Odesivimab-Ebgn) Injection. Available online: https:\/\/www.inmazeb.com\/."},{"key":"ref_38","unstructured":"(2026, March 11). INMAZEB Prescribing Information. Available online: https:\/\/www.regeneron.com\/downloads\/inmazeb_fpi.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Shcherbakov, D.N., Isaeva, A.A., and Mustaev, E.A. (2025). Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies. Antibodies, 14.","DOI":"10.3390\/antib14010022"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105873","DOI":"10.1016\/j.antiviral.2024.105873","article-title":"Ebola-Specific Therapeutic Antibodies from Lab to Clinic: The Example of ZMapp","volume":"226","author":"Wong","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12985-025-02766-y","article-title":"Impact of Most Promising Ebola Therapies on Survival: A Secondary Analysis during the Tenth Outbreak in the Democratic Republic of Congo","volume":"22","author":"Kikwango","year":"2025","journal-title":"Virol. J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kuang, E., Cross, R.W., McCavitt-Malvido, M., Abelson, D.M., Borisevich, V., Stuart, L., Agans, K.N., Mlakar, N., Marimuthu, A., and Deer, D.J. (2022). Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. Pathogens, 11.","DOI":"10.1101\/2022.01.06.475142"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.podrm.2022.11.003","article-title":"Remdesivir","volume":"Volume 48","author":"Bakheit","year":"2023","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hickman, M.R., Saunders, D.L., Bigger, C.A., Kane, C.D., and Iversen, P.L. (2022). The Development of Broad-Spectrum Antiviral Medical Countermeasures to Treat Viral Hemorrhagic Fevers Caused by Natural or Weaponized Virus Infections. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010220"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zumbrun, E.E., Garvey, C.B., Wells, J.B., Lynn, G.C., Van Tongeren, S.A., Steffens, J.T., Wetzel, K.S., Wetzel, D.L., Esham, H.L., and Garza, N.L. (2024). A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques. Viruses, 16.","DOI":"10.3390\/v16121934"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H.T., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.-M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower than Targeted. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105180","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An Update on the Progress of Galidesivir (BCX4430), a Broad-Spectrum Antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cpdd.1037","article-title":"Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects","volume":"11","author":"Mathis","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"eadw0659","DOI":"10.1126\/sciadv.adw0659","article-title":"The Oral Drug Obeldesivir Protects Nonhuman Primates against Lethal Ebola Virus Infection","volume":"11","author":"Woolsey","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102614","DOI":"10.1016\/j.ebiom.2019.102614","article-title":"Clinical Trials in an Ebola Outbreak Seek to Find an Evidence-Based Cure","volume":"52","author":"McMullan","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"El Ayoubi, L.W., Mahmoud, O., Zakhour, J., and Kanj, S.S. (2024). Recent Advances in the Treatment of Ebola Disease: A Brief Overview. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012038"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102601","DOI":"10.1016\/j.ebiom.2019.102601","article-title":"Pharmacokinetics of TKM-130803 in Sierra Leonean Patients with Ebola Virus Disease: Plasma Concentrations Exceed Target Levels, with Drug Accumulation in the Most Severe Patients","volume":"52","author":"Scott","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dunning, J., Kennedy, S.B., Antierens, A., Whitehead, J., Ciglenecki, I., Carson, G., Kanapathipillai, R., Castle, L., Howell-Jones, R., and Pardinaz-Solis, R. (2016). Experimental Treatment of Ebola Virus Disease with Brincidofovir. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162199"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of Advanced Ebola Virus Disease in Nonhuman Primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coph.2021.06.008","article-title":"Recent Developments and Strategies of Ebola Virus Vaccines","volume":"60","author":"Sharma","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola Virus Disease: Current Vaccine Solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/jiad350","article-title":"Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo","volume":"229","author":"Milolo","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ake, J.A., Paolino, K., Hutter, J.N., Cicatelli, S.B., Eller, L.A., Eller, M.A., Costanzo, M.C., Paquin-Proulx, D., Robb, M.L., and Tran, C.L. (2024). Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial. Vaccines, 12.","DOI":"10.3390\/vaccines12050497"},{"key":"ref_61","unstructured":"(2025, November 08). New Vaccine for Prevention of Ebola Virus Disease Recommended for Approval in the European Union, European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/news\/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kuehn, R., Ryan, H., Okwaraeke, K.C., Gould, S., Chaplin, M., Riley, M., Turtle, L., Jacob, S.T., and Fletcher, T. (2024). Vaccines for Preventing Ebola Virus Disease. Cochrane Database Syst. Rev., 2024.","DOI":"10.1002\/14651858.CD015828"},{"key":"ref_63","unstructured":"(2025, November 08). China Approves Ebola Vaccine\u2014Caixin Global. Available online: https:\/\/web.archive.org\/web\/20181007111457\/https:\/\/www.caixinglobal.com\/2017-10-20\/101159251.html."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","article-title":"Open-Label Phase I Clinical Trial of Ad5-EBOV in Africans in China","volume":"13","author":"Wu","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Woolsey, C., and Geisbert, T.W. (2021). Current State of Ebola Virus Vaccines: A Snapshot. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1010078"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and Immunogenicity of GamEvac-Combi, a Heterologous VSV- and Ad5-Vectored Ebola Vaccine: An Open Phase I\/II Trial in Healthy Adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Logunov, D.Y., Dolzhikova, I.V., Boiro, M.Y., Kovyrshina, A.V., Dzharullaeva, A.S., Erokhova, A.S., Grousova, D.M., Tukhvatulin, A.I., Izhaeva, F.M., and Simakova, Y.V. (2025). Safety and Immunogenicity of GamEvac-Combi, a Heterologous rVSV- and rAd5-Vectored Ebola Vaccine: A Randomized Controlled Multicenter Clinical Trial in the Republic of Guinea and Russia. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1487039"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee Adenovirus Vector Ebola Vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41541-024-00833-z","article-title":"Heterologous cAd3-Ebola and MVA-EbolaZ Vaccines Are Safe and Immunogenic in US and Uganda Phase 1\/1b Trials","volume":"9","author":"Happe","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_70","unstructured":"(2026, February 04). Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02718469."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1093\/infdis\/jiad157","article-title":"A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus","volume":"228","author":"Woolsey","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax Vaccine Protects Nonhuman Primates from Viral-Induced Hemorrhagic Fever and Death","volume":"130","author":"Cross","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid Nanoparticle siRNA Treatment of Ebola-Virus-Makona-Infected Nonhuman Primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiz518","article-title":"Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults","volume":"222","author":"Fries","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"An Ebola Whole-Virus Vaccine Is Protective in Nonhuman Primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2017.08.011","article-title":"Genetically Modified Rabies Virus-Vectored Ebola Virus Disease Vaccines Are Safe and Induce Efficacious Immune Responses in Mice and Dogs","volume":"146","author":"Shuai","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1016\/j.celrep.2019.08.047","article-title":"A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge","volume":"28","author":"Woolsey","year":"2019","journal-title":"Cell Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and Immunogenicity of Ebola Virus and Marburg Virus Glycoprotein DNA Vaccines Assessed Separately and Concomitantly in Healthy Ugandan Adults: A Phase 1b, Randomised, Double-Blind, Placebo-Controlled Clinical Trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/s41467-021-22867-w","article-title":"Single-Component Multilayered Self-Assembling Nanoparticles Presenting Rationally Designed Glycoprotein Trimers as Ebola Virus Vaccines","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jfma.2023.06.001","article-title":"Sudan Virus Disease\u2014A Quick Review","volume":"123","author":"Tsou","year":"2024","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"127509","DOI":"10.1016\/j.vaccine.2025.127509","article-title":"The Natural History of Infection with Sudan Virus Compared to Ebola Virus in Non-Human Primates: A Rapid Review","volume":"62","author":"Whitworth","year":"2025","journal-title":"Vaccine"},{"key":"ref_83","unstructured":"(2025, November 11). Sudan Virus Disease (SVD) Caused by Sudan Virus (SUDV), WHO, Regional Office for Africa. Available online: https:\/\/www.afro.who.int\/health-topics\/ebola-disease\/sudan-virus-disease."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Wirchnianski, A.S., Nyakatura, E.K., Herbert, A.S., Kuehne, A.I., Abbasi, S.A., Florez, C., Storm, N., McKay, L.G.A., Dailey, L., and Kuang, E. (2024). Design and Characterization of Protective Pan-Ebolavirus and Pan-Filovirus Bispecific Antibodies. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012134"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMc2313183","article-title":"Sudan Virus Disease among Health Care Workers, Uganda, 2022","volume":"391","author":"Wailagala","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1684","DOI":"10.1016\/S2214-109X(24)00260-2","article-title":"Ebola Disease Outbreak Caused by the Sudan Virus in Uganda, 2022: A Descriptive Epidemiological Study","volume":"12","author":"Kabami","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","article-title":"Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site","volume":"15","author":"Howell","year":"2016","journal-title":"Cell Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1038\/s41467-018-06113-4","article-title":"Structural Basis for Broad Neutralization of Ebolaviruses by an Antibody Targeting the Glycoprotein Fusion Loop","volume":"9","author":"Janus","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e01242-23","DOI":"10.1128\/jvi.01242-23","article-title":"Delayed Treatment of Cynomolgus Macaques with a FVM04\/CA45 Monoclonal Antibody Cocktail Provides Complete Protection against Lethal Sudan Virus Infection","volume":"98","author":"Chan","year":"2024","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"eadk6176","DOI":"10.1126\/science.adk6176","article-title":"Oral Administration of Obeldesivir Protects Nonhuman Primates against Sudan ebolavirus","volume":"383","author":"Cross","year":"2024","journal-title":"Science"},{"key":"ref_92","unstructured":"(2025, November 17). WHO Vaccine Prioritization Working Group. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/who-vaccine-prioritization-report-uganda-ebola-trial-nov-16-2022.pdf."},{"key":"ref_93","unstructured":"(2025, November 17). Evaluation of Safety and Immunogenicity of rVSV\u0394G-SEBOV-GP Vaccine in Adults with Good General Health, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05724472."},{"key":"ref_94","unstructured":"(2025, November 17). PHASE I Sudan Virus Vaccine Development Program. Available online: https:\/\/www.iavi.org\/wp-content\/uploads\/2025\/09\/iavi_fact_sheet_sudv.pdf."},{"key":"ref_95","unstructured":"(2025, November 17). Sudan Virus Disease\u2014Uganda. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON566."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","article-title":"Species-Specific Immunogenicity and Protective Efficacy of a Vesicular Stomatitis Virus-Based Sudan Virus Vaccine: A Challenge Study in Macaques","volume":"4","author":"Marzi","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"101244","DOI":"10.1016\/j.lanmic.2025.101244","article-title":"Fast-Acting Single-Dose Vesicular Stomatitis Virus-Sudan Virus Vaccine: A Challenge Study in Macaques","volume":"6","author":"Fletcher","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_98","unstructured":"(2025, November 17). Sabin ChAd3 Sudan Vaccine. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/amy-finan_sabin-development-strategies_rd-blueprint_ebola-vaccine-consultation_12jan2023.pdf?sfvrsn=502bf10b_3."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Honko, A.N., Hunegnaw, R., Moliva, J.I., Ploquin, A., Dulan, C.N.M., Murray, T., Carr, D., Foulds, K.E., Geisbert, J.B., and Geisbert, T.W. (2024). A Single-Shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure. bioRxiv, Preprint.","DOI":"10.1101\/2024.02.07.579118"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","article-title":"Safety, Tolerability, and Immunogenicity of the Ebola Sudan Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO S) in Healthy Ugandan Adults: A Phase 1, Open-Label, Dose-Escalation Clinical Trial","volume":"23","author":"Mwesigwa","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_101","unstructured":"(2025, November 17). An Overview of ChAdOx1 biEBOV Planned\/Ongoing Clinical Studies\u2014Professor Teresa Lambe. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/teresa-lambe_oxford-development-strategy_rd-blueprint_ebola--vaccine-consultation_12jan2023.pdf?sfvrsn=253cd520_3."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101022","DOI":"10.1016\/j.lanmic.2024.101022","article-title":"Safety and Immunogenicity of a Bivalent Ebola Virus and Sudan Virus ChAdOx1 Vectored Vaccine in Adults in the UK: An Open-Label, Non-Randomised, First-in-Human, Phase 1 Clinical Trial","volume":"6","author":"Jenkin","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1038\/s41467-025-59560-1","article-title":"Single-Dose Replicon RNA Sudan Virus Vaccine Uniformly Protects Female Guinea Pigs from Disease","volume":"16","author":"Anhalt","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_104","unstructured":"(2025, November 17). Bundibugyo Ebolavirus, Sino Biological. Available online: https:\/\/www.sinobiological.com\/research\/virus\/bundibugyo-ebolavirus."},{"key":"ref_105","first-page":"131","article-title":"Resilience and Residuals Beyond Containment: The Hidden Burden of Bundibugyo Ebola Virus Survivorship Sixteen Years On","volume":"2","author":"Kaweesa","year":"2025","journal-title":"VeriXiv"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S712","DOI":"10.1093\/infdis\/jiad207","article-title":"A Recombinant Vesicular Stomatitis Virus\u2013Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection","volume":"228","author":"Woolsey","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"S648","DOI":"10.1093\/infdis\/jiad266","article-title":"A Single-Dose Intranasal Combination Panebolavirus Vaccine","volume":"228","author":"Malherbe","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2239950","DOI":"10.1080\/22221751.2023.2239950","article-title":"Single-Dose VSV-Based Vaccine Protects Cynomolgus Macaques from Disease after Ta\u00ef Forest Virus Infection","volume":"12","author":"Fletcher","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Fletcher, P., O\u2019Donnell, K.L., Rhoderick, J.F., Henderson, C.W., Okumura, A., Bushmaker, T., Cordova, K., Saturday, G., and Marzi, A. (2025). Mucosal Ta\u00ef Forest Virus Infection Causes Disease in Ferrets. PLoS Pathog., 21.","DOI":"10.1371\/journal.ppat.1013579"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41541-024-00985-y","article-title":"Filovirus Vaccines as a Response Paradigm for Emerging Infectious Diseases","volume":"9","author":"Marzi","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/labmed\/lmy046","article-title":"Marburgviruses: An Update","volume":"50","author":"Miraglia","year":"2019","journal-title":"Lab. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"103576","DOI":"10.5501\/wjv.v14.i2.103576","article-title":"Marburg Virus Disease: Emerging Threat, Pathogenesis, and Global Public Health Strategies","volume":"14","author":"Uppala","year":"2025","journal-title":"World J. Virol."},{"key":"ref_113","unstructured":"(2025, November 22). CDC History of Marburg Outbreaks, Available online: https:\/\/www.cdc.gov\/marburg\/outbreaks\/index.html."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3201\/eid2508.190268","article-title":"Marburgvirus in Egyptian Fruit Bats, Zambia","volume":"25","author":"Kajihara","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"107371","DOI":"10.1016\/j.ijid.2024.107371","article-title":"Marburg Virus Reaches Rwanda: How Close Are We to a Vaccine Solution?","volume":"153","author":"Sibomana","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Srivastava, S., Sharma, D., Kumar, S., Sharma, A., Rijal, R., Asija, A., Adhikari, S., Rustagi, S., Sah, S., and Al-qaim, Z.H. (2023). Emergence of Marburg Virus: A Global Perspective on Fatal Outbreaks and Clinical Challenges. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1239079"},{"key":"ref_117","unstructured":"(2025, November 22). CDC About Marburg, Available online: https:\/\/www.cdc.gov\/marburg\/about\/index.html."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"103581","DOI":"10.1016\/j.eclinm.2025.103581","article-title":"Clinical Features of Marburg Virus Disease: A Review of All Reported Patients since 1967","volume":"89","author":"Pisapia","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/infdis\/jiaa290","article-title":"Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus","volume":"222","author":"Porter","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-021-22132-0","article-title":"Combination Therapy Protects Macaques against Advanced Marburg Virus Disease","volume":"12","author":"Cross","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa2415816","article-title":"Marburg Virus Disease in Rwanda, 2024\u2014Public Health and Clinical Responses","volume":"393","author":"Nsanzimana","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMc2313181","article-title":"Case Series of Patients with Marburg Virus Disease, Equatorial Guinea, 2023","volume":"391","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2018.01.011","article-title":"Successful Treatment of Marburg Virus with Orally Administrated T-705 (Favipiravir) in a Mouse Model","volume":"151","author":"Zhu","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of Favipiravir (T-705) in Nonhuman Primates Infected with Ebola Virus or Marburg Virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Musafiri, S., Siddig, E.E., Nkuranga, J.B., Rukundo, A., Mpunga, T., Sendegeya, A., Twagirumugabe, T., Ahmed, A., and Muvunyi, C.M. (2025). Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease. Pathogens, 14.","DOI":"10.3390\/pathogens14040322"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41591-025-03496-y","article-title":"Oral Obeldesivir Provides Postexposure Protection against Marburg Virus in Nonhuman Primates","volume":"31","author":"Cross","year":"2025","journal-title":"Nat. Med."},{"key":"ref_128","unstructured":"(2025, November 29). MBP091 Update- WHO. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/tara-nyhuis_session-4_mappbio_marvac-consultation_10-march-2023.pdf?sfvrsn=c987d645_3."},{"key":"ref_129","unstructured":"WHO Solidarity Partners (2025, November 29). Core Trial Protocol. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/r-d-blueprint-meetings\/pan_filo_4.0_disclaimer.pdf."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/infdis\/jit465","article-title":"Protection Against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated Small Interfering RNA","volume":"209","author":"Mire","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"250ra116","DOI":"10.1126\/scitranslmed.3009706","article-title":"Marburg Virus Infection in Nonhuman Primates: Therapeutic Treatment by Lipid-Encapsulated siRNA","volume":"6","author":"Thi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2022.09.009","article-title":"Combination Treatment of Mannose and GalNAc Conjugated Small Interfering RNA Protects against Lethal Marburg Virus Infection","volume":"31","author":"Ye","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_133","first-page":"1","article-title":"New Research Studies Future Treatments on Marburg Virus","volume":"1","author":"Chouhan","year":"2023","journal-title":"J. Infect. Dis. Treat."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa1410345","article-title":"AVI-7288 for Marburg Virus in Nonhuman Primates and Humans","volume":"373","author":"Heald","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Alsaady, I.M., Bajrai, L.H., Alandijany, T.A., Gattan, H.S., El-Daly, M.M., Altwaim, S.A., Alqawas, R.T., Dwivedi, V.D., and Azhar, E.I. (2023). Cheminformatics Strategies Unlock Marburg Virus VP35 Inhibitors from Natural Compound Library. Viruses, 15.","DOI":"10.3390\/v15081739"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e00226-17","DOI":"10.1128\/mBio.00226-17","article-title":"The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge","volume":"8","author":"Younan","year":"2017","journal-title":"mBio"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1097\/MS9.0000000000003213","article-title":"Therapeutic Advances in Marburg Virus Disease: From Experimental Treatments to Vaccine Development","volume":"87","author":"Paison","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_138","unstructured":"(2025, December 01). cAD3-Marburg Vaccine. Available online: https:\/\/www.vax-before-travel.com\/vaccines\/cad3-marburg-vaccine."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Finch, C.L., King, T.H., Alfson, K.J., Albanese, K.A., Smith, J.N.P., Smock, P., Jakubik, J., Goez-Gazi, Y., Gazi, M., and Dutton, J.W. (2022). Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs. Vaccines, 10.","DOI":"10.3390\/vaccines10111935"},{"key":"ref_140","unstructured":"(2025, December 01). Sabin cAd3-Marburg Vaccine Program Overview. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/marburg-response--building-research-readiness-for-a-future-filovirus-outbreak\/sabin-cad3-marburg-vaccine-programme-overview.pdf?sfvrsn=15014d58_2."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41541-025-01224-8","article-title":"How Rwanda Mounted a Research Response with an Investigational Vaccine Just Ten Days into a Marburg Outbreak","volume":"10","author":"Nsanzimana","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_142","first-page":"773","article-title":"Dengue Fever","volume":"121","author":"Witte","year":"2024","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cell.2015.07.005","article-title":"Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control","volume":"162","author":"Diamond","year":"2015","journal-title":"Cell"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"199018","DOI":"10.1016\/j.virusres.2022.199018","article-title":"Dengue Virus Infection\u2014A Review of Pathogenesis, Vaccines, Diagnosis and Therapy","volume":"324","author":"Kok","year":"2023","journal-title":"Virus Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.jiph.2023.08.001","article-title":"Dengue Overview: An Updated Systemic Review","volume":"16","author":"Khan","year":"2023","journal-title":"J. Infect. Public. Health"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"105710","DOI":"10.1016\/j.meegid.2024.105710","article-title":"Dengue Virus: Etiology, Epidemiology, Pathobiology, and Developments in Diagnosis and Control\u2014A Comprehensive Review","volume":"127","author":"Pourzangiabadi","year":"2025","journal-title":"Infect. Genet. Evol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mjafi.2014.09.011","article-title":"Discovery of Fifth Serotype of Dengue Virus (DENV-5): A New Public Health Dilemma in Dengue Control","volume":"71","author":"Mustafa","year":"2015","journal-title":"Med. J. Armed Forces India"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"821","DOI":"10.15585\/mmwr.mm7230a3","article-title":"Travel-Associated Dengue Cases\u2014United States, 2010\u20132021","volume":"72","author":"Wong","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Salami, D., Capinha, C., Martins, M.D.R.O., and Sousa, C.A. (2020). Dengue Importation into Europe: A Network Connectivity-Based Approach. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230274"},{"key":"ref_150","unstructured":"(2025, December 13). Dengue. Available online: https:\/\/climate-adapt.eea.europa.eu\/en\/observatory\/topics\/health-impacts\/infectious-diseases\/dengue-factsheet."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12098-022-04394-8","article-title":"Management of Dengue: An Updated Review","volume":"90","author":"Tayal","year":"2023","journal-title":"Indian J. Pediatr."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7861\/clinmed.2021-0791","article-title":"Dengue Infection: Global Importance, Immunopathology and Management","volume":"22","author":"Kularatne","year":"2022","journal-title":"Clin. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"h4661","DOI":"10.1136\/bmj.h4661","article-title":"Dengue Fever","volume":"351","author":"Kularatne","year":"2015","journal-title":"BMJ"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1007\/s11030-025-11131-8","article-title":"Drug Repositioning as a Promising Approach for the Eradication of Emerging and Re-Emerging Viral Agents","volume":"29","author":"Almulhim","year":"2025","journal-title":"Mol. Divers."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cmi.2020.05.016","article-title":"Clinical Evidence for Repurposing Chloroquine and Hydroxychloroquine as Antiviral Agents: A Systematic Review","volume":"26","author":"Rodrigo","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cid\/civ949","article-title":"Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"62","author":"Whitehorn","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_157","first-page":"01","article-title":"Antiviral Treatments for Dengue Virus Infections: A Comprehensive Review","volume":"3","author":"Bellah","year":"2024","journal-title":"Pharm. Drug Dev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_159","unstructured":"(2025, December 29). Dengvaxia, European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dengvaxia."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Liu, X. (2025). Opportunities and Challenges of mRNA Technologies in Development of Dengue Virus Vaccine. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1520968"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"25151355211015839","DOI":"10.1177\/25151355211015839","article-title":"Dengvaxia: The World\u2019s First Vaccine for Prevention of Secondary Dengue","volume":"9","author":"Tully","year":"2021","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Anumanthan, G., Sahay, B., and Mergia, A. (2025). Current Dengue Virus Vaccine Developments and Future Directions. Viruses, 17.","DOI":"10.3390\/v17020212"},{"key":"ref_163","first-page":"001831","article-title":"Challenges on the Development of a Dengue Vaccine: A Comprehensive Review of the State of the Art","volume":"104","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.vaccine.2024.01.097","article-title":"Implications of Information Heard about Dengvaxia on Filipinos\u2019 Perception on Vaccination","volume":"42","author":"Mabale","year":"2024","journal-title":"Vaccine"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41591-025-03771-y","article-title":"Efficacy, Public Health Impact and Optimal Use of the Takeda Dengue Vaccine","volume":"31","author":"Ferguson","year":"2025","journal-title":"Nat. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4103\/apjtm.apjtm_259_25","article-title":"Dengue Vaccination: Availability and Relevance to Low- and Middle-Income Countries","volume":"18","author":"Khadka","year":"2025","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_167","unstructured":"(2025, December 29). Data Show Takeda\u2019s Dengue Vaccine Protects Through 7 Years. Available online: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2025\/dengue-vaccine\/."},{"key":"ref_168","unstructured":"(2025, December 29). Takeda 2024 Annual Integrated Report, Better Health for People, Brighter Future for the World. Available online: https:\/\/www.takeda.com\/investors\/annual-integrated-report-2024\/."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e2410018","DOI":"10.71150\/jm.2410018","article-title":"Advancements in Dengue Vaccines: A Historical Overview and pro-Spects for Following next-Generation Candidates","volume":"63","author":"Yan","year":"2025","journal-title":"J. Microbiol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"See, K.C. (2025). Dengue Vaccination: A Practical Guide for Clinicians. Vaccines, 13.","DOI":"10.3390\/vaccines13020145"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Akter, R., Tasneem, F., Das, S., Soma, M.A., Georgakopoulos-Soares, I., Juthi, R.T., and Sazed, S.A. (2024). Approaches of Dengue Control: Vaccine Strategies and Future Aspects. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362780"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Huang, Z., Zhang, Y., Li, H., Zhu, J., Song, W., Chen, K., Zhang, Y., and Lou, Y. (2023). Vaccine Development for Mosquito-Borne Viral Diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1161149"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(23)02576-X","article-title":"Dengue","volume":"403","author":"Adams","year":"2024","journal-title":"Lancet"},{"key":"ref_174","unstructured":"(2025, December 30). Butantan Institute\u2019s Dengue Vaccine, the World\u2019s First Single-Dose Vaccine, Has Been Approved by Anvisa. Johns Hopkins Center for Immunization Research. Available online: https:\/\/centerforimmunizationresearch.org\/butantan-institutes-dengue-vaccine-the-worlds-first-single-dose-vaccine-has-been-approved-by-anvisa."},{"key":"ref_175","first-page":"e00203","article-title":"The Greatest Dengue Epidemic in Brazil: Surveillance, Prevention, and Control","volume":"57","author":"Oliveira","year":"2024","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"107014","DOI":"10.1016\/j.ijid.2024.107014","article-title":"Next-Generation Vaccines for Tropical Infectious Diseases","volume":"143","author":"Allen","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_177","unstructured":"(2025, December 30). Registration of Brazil\u2019s Dengue Vaccine Officially Announced. Available online: https:\/\/agenciabrasil.ebc.com.br\/en\/saude\/noticia\/2025-12\/registration-brazils-dengue-vaccine-officially-announced."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Marangoni, D., Barbiero, A., Spinicci, M., Bartoloni, A., Rossanese, A., Bonanni, P., and Zammarchi, L. (2025). State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature. Infect. Dis. Rep., 17.","DOI":"10.3390\/idr17050117"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Ulgheri, F.M., Bernardes, B.G., and Lancellotti, M. (2025). Decoding Dengue: A Global Perspective, History, Role, and Challenges. Pathogens, 14.","DOI":"10.3390\/pathogens14090954"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41541-022-00537-2","article-title":"Characterization of B-Cell and T-Cell Responses to a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults","volume":"7","author":"Friberg","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4269\/ajtmh.19-0738","article-title":"Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1\/2 Randomized Study","volume":"103","author":"Lin","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/ajim.ajim_108_23","article-title":"Dengue Vaccines: Current Status and Future Perspectives","volume":"12","author":"Kamath","year":"2024","journal-title":"APIK J. Intern. Med."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Santos, J.D., Rocha, K.L.S., Amaral, C.D., Dutra, A.G.S., Figueiredo, P.D.O., Rocha-Vieira, E., De Abreu, F.V.S., Trindade, G.D.S., and De Oliveira, D.B. (2025). The Yellow Fever Outbreak in Brazil (2016\u20132018): How a Low Vaccination Coverage Can Contribute to Emerging Disease Outbreaks. Microorganisms, 13.","DOI":"10.3390\/microorganisms13061287"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.arcmed.2022.10.005","article-title":"Yellow Fever: A Perennial Threat","volume":"53","author":"Tuells","year":"2022","journal-title":"Arch. Med. Res."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Furtado, N.D., Raphael, L.D.M., Ribeiro, I.P., De Mello, I.S., Fernandes, D.R., G\u00f3mez, M.M., Dos Santos, A.A.C., Nogueira, M.D.S., De Castro, M.G., and De Abreu, F.V.S. (2022). Biological Characterization of Yellow Fever Viruses Isolated From Non-Human Primates in Brazil With Distinct Genomic Landscapes. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.757084"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Moreira Salles, A.P., De Seixas Santos Nastri, A.C., Ho, Y.-L., Vilas Boas Casadio, L., Emanuel Amgarten, D., Justo Ar\u00e9valo, S., Soares Gomes-Gouvea, M., Jose Carrilho, F., De Mello Malta, F., and Rebello Pinho, J.R. (2022). Updating the Phylodynamics of Yellow Fever Virus 2016\u20132019 Brazilian Outbreak With New 2018 and 2019 S\u00e3o Paulo Genomes. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.811318"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0053-x","article-title":"Molecular Determinants of Yellow Fever Virus Pathogenicity in Syrian Golden Hamsters: One Mutation Away from Virulence","volume":"7","author":"Klitting","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_188","unstructured":"(2026, March 11). ViralZone-Orthoflavivirus. Available online: https:\/\/viralzone.expasy.org\/24?outline=all_by_species."},{"key":"ref_189","unstructured":"(2026, January 03). CDC Yellow Fever, Available online: https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/yellow-fever.html."},{"key":"ref_190","first-page":"434","article-title":"Yellow Fever: Global Impact, Epidemiology, Pathogenesis, and Integrated Prevention Approaches","volume":"4","author":"Srivastava","year":"2024","journal-title":"Infez. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"11769343241309247","DOI":"10.1177\/11769343241309247","article-title":"Phylodynamic Investigation of Yellow Fever Virus Sheds New Insight on Geographic Dispersal Across Africa","volume":"20","author":"Motayo","year":"2024","journal-title":"Evol. Bioinforma."},{"key":"ref_192","first-page":"427","article-title":"A Review Article on Previous Outbreaks of Yellow Fever and Responses in Nigeria","volume":"64","author":"Kassy","year":"2023","journal-title":"Niger. Med. J."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s44197-025-00341-w","article-title":"Epidemiology of Yellow Fever in Nigeria: Analysis of Climatic, Ecological, Socio-Demographic, and Clinical Factors Associated with Viral Positivity Among Suspected Cases Using National Surveillance Data, 2017\u20132023","volume":"15","author":"Akar","year":"2025","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"126423","DOI":"10.1016\/j.vaccine.2024.126423","article-title":"Breakthroughs and Insights: A Comprehensive Review of Yellow Fever Vaccine Breakthrough Infection across 8 Decades","volume":"43","author":"Coulter","year":"2025","journal-title":"Vaccine"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41541-022-00552-3","article-title":"Yellow Fever Resurgence: An Avoidable Crisis?","volume":"7","author":"Lindsey","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_196","unstructured":"(2026, January 03). Yellow Fever: Outbreaks in East, West and Central Africa. Available online: https:\/\/nathnacyfzone.org.uk\/news\/118\/yellow-fever-outbreaks-in-east-west-and-central-africa."},{"key":"ref_197","unstructured":"(2026, January 03). Yellow Fever, the Returning Epidemic\u2014PAHO\/WHO, Pan American Health Organization. Available online: https:\/\/www.paho.org\/en\/stories\/yellow-fever-returning-epidemic."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.nmni.2025.101580","article-title":"Yellow Fever Outbreaks in South America: Current Epidemiology, Legacies of the Recent Past and Perspectives for the near Future","volume":"65","author":"Angerami","year":"2025","journal-title":"New Microbes New Infect."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1097\/JS9.0000000000000058","article-title":"The Emergence of Yellow Fever: Outbreak, Symptoms, Transmission, Prevention, Treatment, and Possible Consequences","volume":"109","author":"Islam","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_200","unstructured":"(2026, January 03). CDC Symptoms, Diagnosis, and Treatment, Available online: https:\/\/www.cdc.gov\/yellow-fever\/symptoms-diagnosis-treatment\/index.html."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0128-8","article-title":"Yellow Fever in the Diagnostics Laboratory","volume":"7","author":"Domingo","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow Fever Control: Current Epidemiology and Vaccination Strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.virol.2023.06.002","article-title":"Differential Activity of Nucleotide Analogs against Tick-Borne Encephalitis and Yellow Fever Viruses in Human Cell Lines","volume":"585","author":"Binderup","year":"2023","journal-title":"Virology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"105331","DOI":"10.1016\/j.antiviral.2022.105331","article-title":"Remdesivir Efficacy against Yellow Fever in a Hamster Model","volume":"203","author":"Julander","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"De Freitas, C.S., Higa, L.M., Sacramento, C.Q., Ferreira, A.C., Reis, P.A., Delvecchio, R., Monteiro, F.L., Barbosa-Lima, G., James Westgarth, H., and Vieira, Y.R. (2019). Yellow Fever Virus Is Susceptible to Sofosbuvir Both In Vitro and In Vivo. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007072"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e01889-24","DOI":"10.1128\/aac.01889-24","article-title":"Combating Yellow Fever Virus with 7-Deaza-7-Fluoro-2\u2032-C-Methyladenosine","volume":"69","author":"LeCher","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e191665","DOI":"10.1172\/jci.insight.191665","article-title":"Prophylactic and Therapeutic Neutralizing Monoclonal Antibody Treatment Prevents Lethal Yellow Fever Infection","volume":"10","author":"Rust","year":"2025","journal-title":"JCI Insight"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"eade5795","DOI":"10.1126\/scitranslmed.ade5795","article-title":"Therapeutic Neutralizing Monoclonal Antibody Administration Protects against Lethal Yellow Fever Virus Infection","volume":"15","author":"Ricciardi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_209","unstructured":"(2026, January 04). Mabloc and Instituto Butantan Partner to Advance First-in-Class Antibody Therapy for Yellow Fever. Available online: https:\/\/www.mabloc.com\/resources\/mabloc-and-instituto-butantan-partner-to-advance-first-in-class-antibody-therapy-for-yellow-fever."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Hansen, C.A., and Barrett, A.D.T. (2021). The Present and Future of Yellow Fever Vaccines. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090891"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"126758","DOI":"10.1016\/j.vaccine.2025.126758","article-title":"Real-World Evidence of Yellow Fever Vaccination Data-Driven Study","volume":"48","author":"Farnsworth","year":"2025","journal-title":"Vaccine"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S1473-3099(24)00406-7","article-title":"Safety and Immunogenicity of a Next-Generation Live-Attenuated Yellow Fever Vaccine Produced in a Vero Cell Line in the USA: A Phase 1 Randomised, Observer-Blind, Active-Controlled, Dose-Ranging Clinical Trial","volume":"24","author":"Modjarrad","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1895644","DOI":"10.1080\/21645515.2021.1895644","article-title":"Re-Thinking Yellow Fever Vaccines: Fighting Old Foes with New Generation Vaccines","volume":"18","author":"Rollier","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_214","unstructured":"(2026, January 05). CBER-Regulated Products: Resolved Shortages, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-regulated-products-resolved-shortages."},{"key":"ref_215","unstructured":"Hernandez, R. (2026, January 05). GE Healthcare Sells Rights for Inactivated Yellow Fever Vaccine to PnuVax, BioPharm International. Available online: https:\/\/www.biopharminternational.com\/view\/ge-healthcare-sells-rights-inactivated-yellow-fever-vaccine-pnuvax."},{"key":"ref_216","unstructured":"(2026, January 05). Trial of Yellow Fever Inactivated Vaccine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00995865."},{"key":"ref_217","unstructured":"(2026, January 05). News, Bavarian Nordic. Available online: https:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=5025."},{"key":"ref_218","unstructured":"(2026, January 05). MONTANIDETM ISA W\/O, Ready-to-Use Adjuvants for Water-in-Oil Emulsion Vaccines. Available online: https:\/\/www.seppic.com\/product\/montanide-isa-wo."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Julander, J.G., Testori, M., Cheminay, C., and Volkmann, A. (2018). Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01756"},{"key":"ref_220","unstructured":"(2026, January 05). A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18\u201345 Year Old Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02743455."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Weiss, A., Touret, F., Baronti, C., Gilles, M., Hoen, B., Nougair\u00e8de, A., De Lamballerie, X., and Sommer, M.O.A. (2021). Niclosamide Shows Strong Antiviral Activity in a Human Airway Model of SARS-CoV-2 Infection and a Conserved Potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta Variant (B.1.617.2). PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260958"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Bohra, B., Srivastava, K.S., Raj, A., Pal, N., and Shukla, R. (2025). Kyasanur Forest Disease Virus: Epidemiological Insights, Pathogenesis, Therapeutic Strategies, and Advances in Vaccines and Diagnostics. Viruses, 17.","DOI":"10.20944\/preprints202505.1961.v1"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","article-title":"Evaluation of Sofosbuvir (\u03b2-D-2\u2032-Deoxy-2\u2032-\u03b1-Fluoro-2\u2032-\u03b2-C-Methyluridine) as an Inhibitor of Dengue Virus Replication #","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"2580154","DOI":"10.1080\/21505594.2025.2580154","article-title":"Pathogenicity and Virulence of Kyasanur Forest Disease: A Comprehensive Review of an Expanding Zoonotic Threat in Southwestern India","volume":"16","author":"Kaushal","year":"2025","journal-title":"Virulence"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41541-021-00416-2","article-title":"A Live-Attenuated Viral Vector Vaccine Protects Mice against Lethal Challenge with Kyasanur Forest Disease Virus","volume":"6","author":"Bhatia","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"eadj1428","DOI":"10.1126\/sciadv.adj1428","article-title":"Single-Dose VSV-Based Vaccine Protects against Kyasanur Forest Disease in Nonhuman Primates","volume":"9","author":"Bhatia","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e18982","DOI":"10.7717\/peerj.18982","article-title":"Construction of an Immunoinformatics-Based Multi-Epitope Vaccine Candidate Targeting Kyasanur Forest Disease Virus","volume":"13","author":"Kasibhatla","year":"2025","journal-title":"PeerJ"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Diani, E., Cecchetto, R., Tonon, E., Mantoan, M., Lotti, V., Lagni, A., Palmisano, A., Piccaluga, P.P., and Gibellini, D. (2025). Omsk Hemorrhagic Fever Virus: A Comprehensive Review from Epidemiology to Diagnosis and Treatment. Microorganisms, 13.","DOI":"10.3390\/microorganisms13020426"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"RCR5142","DOI":"10.59761\/RCR5142","article-title":"Small Molecules against Viruses Causing Hemorrhagic Fevers in Russia","volume":"93","author":"Laev","year":"2024","journal-title":"Russ. Chem. Rev."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Alnuqaydan, A.M., and Eisa, A.A. (2024). Targeting Polyprotein to Design Potential Multiepitope Vaccine against Omsk Hemorrhagic Fever Virus (OHFV) by Evaluating Allergenicity, Antigenicity, and Toxicity Using Immunoinformatic Approaches. Biology, 13.","DOI":"10.3390\/biology13090738"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","article-title":"Current Perspectives on Vaccines and Therapeutics for Lassa Fever","volume":"21","author":"Warner","year":"2024","journal-title":"Virol. J."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Reyna, R., Littlefield, K., Shehu, N., Makishima, T., Maruyama, J., and Paessler, S. (2024). The Importance of Lassa Fever and Its Disease Management in West Africa. Viruses, 16.","DOI":"10.3390\/v16020266"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Salam, A.P., Duvignaud, A., Jaspard, M., Malvy, D., Carroll, M., Tarning, J., Olliaro, P.L., and Horby, P.W. (2022). Ribavirin for Treating Lassa Fever: A Systematic Review of Pre-Clinical Studies and Implications for Human Dosing. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010289"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14760584.2023.2290683","article-title":"Progress toward the Development of Lassa Vaccines","volume":"23","author":"Ly","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_235","unstructured":"(2026, January 08). A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV\u2206G-LASV-GPC Vaccine in Adults in Good General Heath, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04794218."},{"key":"ref_236","unstructured":"(2026, January 08). A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05868733."},{"key":"ref_237","unstructured":"(2026, January 08). Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03805984."},{"key":"ref_238","unstructured":"(2026, January 08). A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04055454."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/tmi.13876","article-title":"Lassa Fever Vaccine Candidates: A Scoping Review of Vaccine Clinical Trials","volume":"28","author":"Sulis","year":"2023","journal-title":"Trop. Med. Int. Health"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"e2419","DOI":"10.1002\/rmv.2419","article-title":"Poonam Recent Developments on Junin Virus, a Causative Agent for Argentine Haemorrhagic Fever","volume":"33","author":"Kumar","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"105444","DOI":"10.1016\/j.antiviral.2022.105444","article-title":"Severe Mammarenaviral Disease in Guinea Pigs Effectively Treated by an Orally Bioavailable Fusion Inhibitor, Alone or in Combination with Favipiravir","volume":"208","author":"Westover","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Iyer, K., Yan, Z., and Ross, S.R. (2024). Entry Inhibitors as Arenavirus Antivirals. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1382953"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Zadeh, V.R., Afowowe, T.O., Abe, H., Urata, S., and Yasuda, J. (2022). Potential and Action Mechanism of Favipiravir as an Antiviral against Junin Virus. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010689"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e00112","DOI":"10.1128\/jvi.00112-24","article-title":"Restoration of Virulence in the Attenuated Candid#1 Vaccine Virus Requires Reversion at Both Positions 168 and 427 in the Envelope Glycoprotein GPC","volume":"98","author":"Nunberg","year":"2024","journal-title":"J. Virol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00284-025-04320-z","article-title":"A New Vaccine Candidate Expressing JUNV GP1\u2013GP2 Against Argentine Hemorrhagic Fever Based on Baculovirus Surface Display","volume":"82","author":"Tomatis","year":"2025","journal-title":"Curr. Microbiol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41579-023-00871-9","article-title":"Crimean\u2013Congo Haemorrhagic Fever Virus","volume":"21","author":"Hawman","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_247","first-page":"421","article-title":"Crimean-Congo Haemorrhagic Fever (CCHF): Present and Future Therapeutic Armamentarium","volume":"4","year":"2024","journal-title":"Infez. Med."},{"key":"ref_248","unstructured":"(2026, January 10). UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF (UMIT-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05940545?tab=ta-ble."},{"key":"ref_249","unstructured":"(2026, January 10). First Volunteers Receive Vaccine for Crimean-Congo Haemorrhagic Fever in Oxford Clinical Trial, University of Oxford. Available online: https:\/\/www.ox.ac.uk\/news\/2023-09-11-first-volunteers-receive-vaccine-crimean-congo-haemorrhagic-fever-oxford-clinical."},{"key":"ref_250","unstructured":"(2026, January 10). Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06799013."},{"key":"ref_251","unstructured":"(2026, January 10). Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever (CCHF-NP-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06684431."},{"key":"ref_252","unstructured":"(2026, January 10). A First-in-Human Study to Assess the Safety of an MVA-Based Vaccine for Crimean-Congo Haemorrhagic Fever (MVA-CCHF) and the Vaccine\u2019s Ability to Generate an Immune Response. Available online: https:\/\/www.isrctn.com\/ISRCTN14935155."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Afzal, S., Ali, L., Batool, A., Afzal, M., Kanwal, N., Hassan, M., Safdar, M., Ahmad, A., and Yang, J. (2023). Hantavirus: An Overview and Advancements in Therapeutic Approaches for Infection. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1233433"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s40506-020-00236-3","article-title":"Hantavirus Infections\u2014Treatment and Prevention","volume":"12","author":"Dheerasekara","year":"2020","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Sehgal, A., Mehta, S., Sahay, K., Martynova, E., Rizvanov, A., Baranwal, M., Chandy, S., Khaiboullina, S., Kabwe, E., and Davidyuk, Y. (2023). Hemorrhagic Fever with Renal Syndrome in Asia: History, Pathogenesis, Diagnosis, Treatment, and Prevention. Viruses, 15.","DOI":"10.3390\/v15020561"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"eadg1855","DOI":"10.1126\/scitranslmed.adg1855","article-title":"Structural and Mechanistic Basis of Neutralization by a Pan-Hantavirus Protective Antibody","volume":"15","author":"Mittler","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Chai, S., Wang, L., Du, H., and Jiang, H. (2025). Achievement and Challenges in Orthohantavirus Vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13020198"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-024-00814-2","article-title":"Single Dose Recombinant VSV Based Vaccine Elicits Robust and Durable Neutralizing Antibody against Hantaan Virus","volume":"9","author":"Zhang","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cll.2017.01.004","article-title":"Rift Valley Fever","volume":"37","author":"Hartman","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/fvl-2017-0060","article-title":"Recent Advances in the Development of Antiviral Therapeutics for Rift Valley Fever Virus Infection","volume":"12","author":"Atkins","year":"2017","journal-title":"Future Virol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e01467-25","DOI":"10.1128\/mbio.01467-25","article-title":"Effective Treatment of Advanced Oropouche Virus, Rift Valley Fever Virus, and Dabie Bandavirus Infections with 4\u2032-Fluorouridine","volume":"16","author":"Westover","year":"2025","journal-title":"mBio"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Nair, N., Osterhaus, A.D.M.E., Rimmelzwaan, G.F., and Prajeeth, C.K. (2023). Rift Valley Fever Virus\u2014Infection, Pathogenesis and Host Immune Responses. Pathogens, 12.","DOI":"10.3390\/pathogens12091174"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1473-3099(25)00565-1","article-title":"Safety, Tolerability, and Immunogenicity of the ChAdOx1 RVF Vaccine against Rift Valley Fever among Healthy Adults in Uganda: A Single-Centre, Single-Blind, Randomised, Placebo-Controlled, Dose-Escalation, Phase 1 Trial","volume":"26","author":"Anywaine","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1473-3099(23)00068-3","article-title":"Safety and Immunogenicity of a ChAdOx1 Vaccine against Rift Valley Fever in UK Adults: An Open-Label, Non-Randomised, First-in-Human Phase 1 Clinical Trial","volume":"23","author":"Jenkin","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Kitandwe, P.K., McKay, P.F., Kaleebu, P., and Shattock, R.J. (2022). An Overview of Rift Valley Fever Vaccine Development Strategies. Vaccines, 10.","DOI":"10.3390\/vaccines10111794"},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Mire, C.E., and Marzi, A. (2022). Hemorrhagic Fever Viruses: Pathogenesis and Countermeasures. Microorganisms, 10.","DOI":"10.3390\/microorganisms10030591"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features That Contribute to Protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal Antibody Pharmacokinetics and Pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.copbio.2009.10.006","article-title":"Formulation and Manufacturability of Biologics","volume":"20","author":"Shire","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tibtech.2014.05.005","article-title":"Therapeutic Protein Aggregation: Mechanisms, Design, and Control","volume":"32","author":"Roberts","year":"2014","journal-title":"Trends Biotechnol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of Monoclonal Antibodies and Fc-Fusion Proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.09.20","article-title":"Opportunities and Challenges of Developing Thermostable Vaccines","volume":"8","author":"Chen","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine Instability in the Cold Chain: Mechanisms, Analysis and Formulation Strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Covarrubias, C.E., Rivera, T.A., Soto, C.A., Deeks, T., and Kalergis, A.M. (2022). Current GMP Standards for the Production of Vaccines and Antibodies: An Overview. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1021905"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2021.02.033","article-title":"Next Generation Live-Attenuated Yellow Fever Vaccine Candidate: Safety and Immuno-Efficacy in Small Animal Models","volume":"39","author":"Raynal","year":"2021","journal-title":"Vaccine"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tibtech.2010.02.001","article-title":"Recent Advances in Large-Scale Production of Monoclonal Antibodies and Related Proteins","volume":"28","author":"Shukla","year":"2010","journal-title":"Trends Biotechnol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/4\/426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:14:17Z","timestamp":1775189657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/4\/426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":276,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pharmaceutics18040426"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18040426","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}